Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Gains from Sales and Divestitures: 2015-2024

Historic Gains from Sales and Divestitures for Iovance Biotherapeutics (IOVA) over the last 5 years, with Dec 2024 value amounting to $3.2 million.

  • Iovance Biotherapeutics' Gains from Sales and Divestitures rose 61.68% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 61.68%. This contributed to the annual value of $3.2 million for FY2024, which is 151.32% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Gains from Sales and Divestitures stood at $3.2 million for FY2024, which was up 151.32% from $1.3 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Gains from Sales and Divestitures ranged from a high of $3.2 million in FY2024 and a low of $1.3 million during FY2023.
  • Over the past 2 years, Iovance Biotherapeutics' median Gains from Sales and Divestitures value was $2.2 million (recorded in 2023), while the average stood at $2.2 million.
  • Data for Iovance Biotherapeutics' Gains from Sales and Divestitures shows a peak YoY soared of 151.32% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Iovance Biotherapeutics' Gains from Sales and Divestitures stood at $1.3 million in 2023, then surged by 151.32% to $3.2 million in 2024.